Core Insights - The stock of Meihao Medical (301363) closed at 23.51 yuan on October 31, 2025, with a rise of 2.71% and a trading volume of 59,900 hands, amounting to a total transaction value of 141 million yuan [1] Financial Performance - For the first three quarters of 2025, Meihao Medical reported a main business revenue of 1.194 billion yuan, an increase of 3.28% year-on-year, while the net profit attributable to shareholders was 208 million yuan, a decrease of 19.25% year-on-year [3] - In Q3 2025, the company achieved a single-quarter main business revenue of 462 million yuan, up 2.56% year-on-year, and a net profit attributable to shareholders of 93.90 million yuan, an increase of 5.89% year-on-year [3] - The company's gross profit margin stands at 39.34% [3] Market Position - Meihao Medical's total market capitalization is 13.374 billion yuan, which is higher than the industry average of 11.561 billion yuan, ranking 23rd out of 124 in the medical device industry [3] - The company's price-to-earnings ratio (P/E) is 48.18, which is lower than the industry average of 62.61, ranking 53rd out of 124 [3] - The net profit margin of Meihao Medical is 17.43%, significantly higher than the industry average of 9.57%, ranking 42nd out of 124 [3] Investment Sentiment - In the last 90 days, 17 institutions have rated the stock, with 15 buy ratings and 2 hold ratings, and the average target price set by institutions is 25.2 yuan [4]
股票行情快报：美好医疗（301363）10月31日主力资金净卖出565.88万元